Skip to content
Head to head

Oric Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ORIC · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

ORIC -39.0%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
ORICVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price7.36515.02
Change today-4.42%-1.08%
1-year return-35.9%+22.0%
Market cap$764.94M$130.58B
52-week range7.23 – 14.68412.27 – 568.67
Valuation
P/E (TTM)-5.1133.14
P/E percentile, own 5-yr range26th99th
P/B2.256.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.4715.32
Net profit (TTM)$-152.78M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-06-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-112.26M$3.20B
Provider cash-flow period date2026-06-292026-09-29
Ownership & sentiment
Institutional ownership120.8%96.8%
Insider activity (12mo)23 buy / 27 sell28 buy / 22 sell
Short interest (% of float)10.4%1.9%
Analyst consensus100% buy (8)95% buy / 5% hold (21)
Analyst price target$24 (+220%)$624 (+21%)
StockVane view
StockVane Quant RatingE (11)C (68)
Company
Employees1046,400
Founded20141989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.